Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim

Last Updated: August 14, 2022

Details for Patent: 6,888,027

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 6,888,027 protect, and when does it expire?

Patent 6,888,027 protects BELEODAQ and is included in one NDA.

This patent has eighteen patent family members in eleven countries.

Summary for Patent: 6,888,027
Title: Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors
Abstract:This invention pertains to certain active carbamic acid compounds which inhibit HDAC activity and which have the following formula: (I) A is an aryl group; Q.sup.1 is a covalent bond or an aryl leader group; J is a sulfonamide linkage selected from: --S(.dbd.O).sub.2 NR.sup.1 -- and --NR.sup.1 S(.dbd.O).sub.2 --; R1 is a sulfonamido substituent; and, Q.sup.2 is an acid leader group; with the proviso that if J is --S(.dbd.O).sub.2 NR.sup.1 --, then Q.sup.1 is an aryl leader group; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC, and, e.g., to inhibit proliferative conditions, such as cancer and psoriasis. ##STR1##
Inventor(s): Watkins; Clare J (Abingdon, GB), Romero-Martin; Maria Rosario (Didcot, GB), Moore; Kathryn G (Abingdon, GB), Ritchie; James (Abingdon, GB), Finn; Paul W (Abingdon, GB), Kalvinsh; Ivars (Riga, LV), Loza; Einars (Riga, LV), Dikovska; Klara (Riga, LV), Gailite; Vija (Riga, LV), Vorona; Maxim (Riga, LV), Piskunova; Irina (Riga, LV), Starchenkov; Igor (Riga, LV), Andrianov; Victor (Riga, LV), Harris; C. John (Sittingbourne, GB), Duffy; James E. S. (Sittingbourne, GB)
Assignee: Topotarget UK Limited (Abingdon, GB)
Application Number:10/381,790
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,888,027
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 6,888,027

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Acrotech BELEODAQ belinostat POWDER;INTRAVENOUS 206256-001 Jul 3, 2014 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA (PTCL). See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 6,888,027

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0023986Sep 29, 2000
PCT Information
PCT FiledSeptember 27, 2001PCT Application Number:PCT/GB01/04326
PCT Publication Date:April 18, 2002PCT Publication Number: WO02/30879

International Family Members for US Patent 6,888,027

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2001290131 See Plans and Pricing
Australia 9013101 See Plans and Pricing
Canada 2423744 See Plans and Pricing
Canada 2765409 See Plans and Pricing
Cyprus 1114818 See Plans and Pricing
Denmark 1328510 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.